【摘要】 长期以来,抗肿瘤药物在个体间的毒性差异受到临床医生的高度关注,其临床毒性的发生不仅与患者的年龄、性别以及药物间相互作用等因素有关,而且和参与药物代谢的蛋白、药物作用靶标及药物转运体的活性与表达水平密切相关。其中,药物转运体介导某些药物的吸收、分布和消除等过程,在药理学和临床中具有重要意义。本文就目前关于转运体参与抗肿瘤药物毒性发生机制的研究进行综述,阐明药物转运体在毒性发生中的作用,为有效规避或减少转运体参与的抗肿瘤药物毒性反应,促进临床合理用药及抗肿瘤个体化治疗提供参考。更多还原

【Abstract】 Differences of the individual toxic effects of antitumor drugs have been a concern in clinical treatment of cancers. The drug toxicity was not only related to the age, sex, and drug interactions, but also to the expression of protein involved in the metabolism, targets and transporters of drugs. Drug transporter mediates the absorption, distribution and elimination of some drugs, which exhibits a great significance in pharmacology and clinical practice. The purpose of this review is to provide information regarding transporter-medicated toxic effects of antitumor drugs in order to reduce or avoid the transporter-medicated toxic effects, and to promote reasonable drug use and individualized application of antitumor drugs in clinics.更多还原